Summary of the 5th Conference on Retroviruses and Opportunistic Infections.

Research output: Contribution to journalArticle

Abstract

Research highlights from the Fifth Conference on Retroviruses and Opportunistic Infections are presented in the following five areas: 1) major messages concerning AIDS treatment and outcomes; 2) research findings on new antiretroviral agents; 3) prevention and treatment of opportunistic infections; 4) research on HIV transmission routes and rapid test strategies for HIV; and 5) the cost of AIDS health care and resource allocation. Important information delivered at the conference includes research on CD4 cell response during acute retroviral syndrome and long-term prognosis, viral burden nadir predicting long-term antiviral success, opportunistic infections and viral burden under 5,000, impaired phosphorylation after prolonged AZT therapy, and successful salvage in patients failing indinavir. The most important observations of antiretroviral agents are discussed for the following drugs: amprenavir, efavirenz, abacavir, and adefovir. Additional research is summarized on the reduction in the frequency of opportunistic infections in the age of highly active antiretroviral therapy (HAART), including the frequency of resistance during treatment of CMV retinitis and the treatment of tuberculosis and viral burden. Tables include results from selected clinical trials of antiretroviral therapy and results from research on salvage regimens. Finally, evidence is highlighted revealing that the cost of hospitalization has been substantially reduced but is offset by pharmaceutical costs.

Original languageEnglish (US)
JournalThe Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service
Volume10
Issue number2
StatePublished - 1998
Externally publishedYes

Fingerprint

Opportunistic Infections
Viral Load
Research
Anti-Retroviral Agents
efavirenz
Costs and Cost Analysis
Acquired Immunodeficiency Syndrome
HIV
Indinavir
Retinitis
Salvage Therapy
Resource Allocation
Health Resources
Highly Active Antiretroviral Therapy
Therapeutics
Pharmaceutical Preparations
Antiviral Agents
Tuberculosis
Hospitalization
Phosphorylation

Cite this

@article{ae5ee67e90594f3bbe04976871e91f3c,
title = "Summary of the 5th Conference on Retroviruses and Opportunistic Infections.",
abstract = "Research highlights from the Fifth Conference on Retroviruses and Opportunistic Infections are presented in the following five areas: 1) major messages concerning AIDS treatment and outcomes; 2) research findings on new antiretroviral agents; 3) prevention and treatment of opportunistic infections; 4) research on HIV transmission routes and rapid test strategies for HIV; and 5) the cost of AIDS health care and resource allocation. Important information delivered at the conference includes research on CD4 cell response during acute retroviral syndrome and long-term prognosis, viral burden nadir predicting long-term antiviral success, opportunistic infections and viral burden under 5,000, impaired phosphorylation after prolonged AZT therapy, and successful salvage in patients failing indinavir. The most important observations of antiretroviral agents are discussed for the following drugs: amprenavir, efavirenz, abacavir, and adefovir. Additional research is summarized on the reduction in the frequency of opportunistic infections in the age of highly active antiretroviral therapy (HAART), including the frequency of resistance during treatment of CMV retinitis and the treatment of tuberculosis and viral burden. Tables include results from selected clinical trials of antiretroviral therapy and results from research on salvage regimens. Finally, evidence is highlighted revealing that the cost of hospitalization has been substantially reduced but is offset by pharmaceutical costs.",
author = "John Bartlett",
year = "1998",
language = "English (US)",
volume = "10",
journal = "The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service",
issn = "1551-8396",
publisher = "Johns Hopkins University Press",
number = "2",

}

TY - JOUR

T1 - Summary of the 5th Conference on Retroviruses and Opportunistic Infections.

AU - Bartlett, John

PY - 1998

Y1 - 1998

N2 - Research highlights from the Fifth Conference on Retroviruses and Opportunistic Infections are presented in the following five areas: 1) major messages concerning AIDS treatment and outcomes; 2) research findings on new antiretroviral agents; 3) prevention and treatment of opportunistic infections; 4) research on HIV transmission routes and rapid test strategies for HIV; and 5) the cost of AIDS health care and resource allocation. Important information delivered at the conference includes research on CD4 cell response during acute retroviral syndrome and long-term prognosis, viral burden nadir predicting long-term antiviral success, opportunistic infections and viral burden under 5,000, impaired phosphorylation after prolonged AZT therapy, and successful salvage in patients failing indinavir. The most important observations of antiretroviral agents are discussed for the following drugs: amprenavir, efavirenz, abacavir, and adefovir. Additional research is summarized on the reduction in the frequency of opportunistic infections in the age of highly active antiretroviral therapy (HAART), including the frequency of resistance during treatment of CMV retinitis and the treatment of tuberculosis and viral burden. Tables include results from selected clinical trials of antiretroviral therapy and results from research on salvage regimens. Finally, evidence is highlighted revealing that the cost of hospitalization has been substantially reduced but is offset by pharmaceutical costs.

AB - Research highlights from the Fifth Conference on Retroviruses and Opportunistic Infections are presented in the following five areas: 1) major messages concerning AIDS treatment and outcomes; 2) research findings on new antiretroviral agents; 3) prevention and treatment of opportunistic infections; 4) research on HIV transmission routes and rapid test strategies for HIV; and 5) the cost of AIDS health care and resource allocation. Important information delivered at the conference includes research on CD4 cell response during acute retroviral syndrome and long-term prognosis, viral burden nadir predicting long-term antiviral success, opportunistic infections and viral burden under 5,000, impaired phosphorylation after prolonged AZT therapy, and successful salvage in patients failing indinavir. The most important observations of antiretroviral agents are discussed for the following drugs: amprenavir, efavirenz, abacavir, and adefovir. Additional research is summarized on the reduction in the frequency of opportunistic infections in the age of highly active antiretroviral therapy (HAART), including the frequency of resistance during treatment of CMV retinitis and the treatment of tuberculosis and viral burden. Tables include results from selected clinical trials of antiretroviral therapy and results from research on salvage regimens. Finally, evidence is highlighted revealing that the cost of hospitalization has been substantially reduced but is offset by pharmaceutical costs.

UR - http://www.scopus.com/inward/record.url?scp=0032014296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032014296&partnerID=8YFLogxK

M3 - Article

C2 - 11365136

AN - SCOPUS:0032014296

VL - 10

JO - The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service

JF - The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service

SN - 1551-8396

IS - 2

ER -